In vivo antitumor effects of chitosan-conjugated docetaxel after oral administration

Lee, Eun‐Hye; Kim, Hyungjun; Lee, In-Hyun; Jon, Sangyong

doi:10.1016/j.jconrel.2009.08.014

Cited by 132 publications

(57 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lee et al prepared a conjugate with DTX and low molecular weight chitosan (LMWC) via a cleavable linker. 35 The water solubility of DTX was increased by approximately 200-fold after conjugation with LMWC. The LMWC-DTX conjugate had antitumor efficacy comparable to DTX but was revealed to have much lower subacute toxicity.…”

Section: Polymer-drug Conjugatesmentioning

confidence: 99%

How nanotechnology can enhance docetaxel therapy

Zhang¹,

Zhang²

2013

IJN

101

View full text Add to dashboard Cite

Docetaxel has been recognized as one of the most efficient anticancer drugs over the past decade; however, its poor water solubility and systemic toxicity have greatly limited its clinical application. In recent decades, the emergence of nanotechnology has provided new drug delivery systems for docetaxel, which can improve its water solubility, minimize the side effects and increase the tumor-targeting distribution by passive or active targeting. This review focuses on the research progress in nanoformulations related to docetaxel delivery -such as polymer-based, lipid-based, and lipid-polymer hybrid nanocarriers, as well as inorganic nanoparticles -addressing their structures, characteristics, preparation, physicochemical properties, methods by which drugs are loaded into them, and their in vitro and in vivo efficacies. Further, the targeted ligands used in the docetaxel nanoformulations, such as monoclonal antibodies, peptides, folic acid, transferrin, aptamers and hyaluronic acid, are described. The issues to overcome before docetaxel nanoformulations can be used in clinical and commercial applications are also discussed.

show abstract

Section: Polymer-drug Conjugatesmentioning

confidence: 99%

How nanotechnology can enhance docetaxel therapy

Zhang¹,

Zhang²

2013

IJN

101

View full text Add to dashboard Cite

show abstract

“…7,8 Multidrug resistance is another problem inherent to DOC. To overcome these disadvantages and to improve solubility of DOC, alternative methods of drug delivery have been suggested, including liposomes, 9,10 nanoparticles, 11,12 micelles, 13 prodrugs, 14 macromolecular conjugates, 15 and cyclodextrins. 16 Microemulsions (MEs) are transparent, thermodynamically stable isotropic mixtures of oil, water, and surfactant, and are frequently combined with a cosurfactant.…”

Section: Introductionmentioning

confidence: 99%

Intravenous microemulsion of docetaxel containing an anti-tumor synergistic ingredient (Brucea javanica oil): formulation and pharmacokinetics

Shi-lin¹,

Chen²,

Ye³

et al. 2013

IJN

View full text Add to dashboard Cite

“…Docetaxel is used as a model hydrophobic anticancer drug, and shows high anticancer efficacy in patients with ovarian carcinoma, lung cancer, advanced breast cancer, and head/neck cancer. 12 The incorporation of PEG can prolong the residence time of liposomes in the blood, and efficient folate receptor binding and endocytosis of folate-derived liposomes can be achieved by separating folate from the liposomal surface when a PEG spacer is used, 13 for the reason that folic acid has the flexibility to interact with the corresponding cell surface receptor.…”

Section: Introductionmentioning

confidence: 99%

In vitro and in vivo evaluation of folate receptor-targeting amphiphilic copolymer-modified liposomes loaded with docetaxel

Li¹,

Tian²,

Zhang³

et al. 2011

IJN

View full text Add to dashboard Cite

Background: The purpose of this study was to develop folate-poly (PEG-cyanoacrylate-co-cholesteryl cyanoacrylate) (FA-PEG-PCHL)-modified freeze-dried liposomes for targeted chemotherapy using docetaxel as a model drug. Methods: FA-PEG-PCHL was synthesized and its cytotoxicity was evaluated by CCK-8 assay in L929. Docetaxel-loaded liposomes modified by FA-PEG-PCHL were prepared by an organic solvent injection method and lyophilized to obtain freeze-dried FA-PEG-PCHL-docetaxel liposomes (FA-PDCT-L). Two carcinoma cell lines (MCF-7 and A-549 cells) were cultured with docetaxel solution, conventional docetaxel-loaded liposomes, or FA-PDCT-L, and the cytotoxicity and apoptosis was evaluated for each preparation. The uptake of the docetaxel preparations into MCF-7 cells was studied by confocal laser scanning microscopy. Liquid chromatography-mass spectrometry was used to study the pharmacokinetics and tissue distribution characteristics of the preparations. Results: The existence of an enlarged fixed aqueous layer on the surface of the liposomes was affirmed by zeta potential analysis. The entrapment efficiency and particle size distribution were almost the same as those of docetaxel-loaded liposomes. The drug release profile showed that the release rate was faster at higher molecular weight of the polymer. Compared with docetaxel solution and docetaxel-loaded liposomes, FA-PDCT-L demonstrated the strongest cytotoxicity against two carcinoma cell lines, the greatest intracellular uptake especially in the nucleus, as well as the most powerful apoptotic efficacy. In pharmacokinetic studies, the area under the plasma concentration-time curve of FA-PDCT-L was increased 3.82 and 6.23 times in comparison with the values for the docetaxel-loaded liposomes and docetaxel solution, respectively. Meanwhile, a lower concentration of docetaxel was observed for FA-PDCT-L in the liver and spleen, and a significantly higher concentration of FA-PDCT-L in tumors suggested that the presence of FA-PEG-PCHL on the liposomes resulted in greater accumulation of the drug in tumor tissue. Conclusion: Liposomes modified by FA-PEG-PCHL could be one of the promising suspensions for the delivery of antitumor drugs in cancer.

show abstract

In vivo antitumor effects of chitosan-conjugated docetaxel after oral administration

Cited by 132 publications

References 37 publications

How nanotechnology can enhance docetaxel therapy

How nanotechnology can enhance docetaxel therapy

Intravenous microemulsion of docetaxel containing an anti-tumor synergistic ingredient (Brucea javanica oil): formulation and pharmacokinetics

In vitro and in vivo evaluation of folate receptor-targeting amphiphilic copolymer-modified liposomes loaded with docetaxel

Contact Info

Product

Resources

About